Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Key Points • Nivolumab + BV showed durable safety and efficacy as salvage in patients with R/R PMBL after 3-year follow-up, with no new safety signals.• High 2-year complete response rates (80%-100%) after subsequent HCT indicate potential for nivo + BV as a bridging therapy to transplant.

[1]  M. Shipp,et al.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. , 2023, Blood.

[2]  H. Prince,et al.  Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives , 2022, Annals of Hematology.

[3]  M. Kersten,et al.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma , 2021, New England Journal of Medicine.

[4]  I. Moiseev,et al.  Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma , 2021, International Journal of Clinical Oncology.

[5]  N. Shukla,et al.  Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. , 2021, Transplantation and cellular therapy.

[6]  N. Johnson,et al.  NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY , 2021, Hematological Oncology.

[7]  R. Advani,et al.  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. , 2021, Blood.

[8]  R. Advani,et al.  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. , 2020, The Lancet. Haematology.

[9]  J. Serody,et al.  Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Michael L. Wang,et al.  Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. , 2020, Blood advances.

[11]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[12]  B. Hankey,et al.  Surveillance, Epidemiology, and End Results Program , 2020, Definitions.

[13]  Andrew J. Dunford,et al.  Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. , 2019, Blood.

[14]  G. Salles,et al.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Lauren C. Chong,et al.  Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. , 2019, Blood.

[16]  N. Johnson,et al.  Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Salles,et al.  Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies , 2018, Blood.

[18]  A. Zelenetz,et al.  Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Advani,et al.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. , 2018, Blood.

[21]  P. Zinzani,et al.  Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. , 2017, Blood.

[22]  L. Scott.  Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma , 2017, Drugs.

[23]  Wen-Qi Jiang,et al.  Racial patterns of patients with primary mediastinal large B-cell lymphoma , 2016, Medicine.

[24]  M. Gleeson,et al.  R-CHOP in primary mediastinal B-Cell lymphoma (PMBL): results from the UK NCRI R-CHOP 14 v 21 trial. , 2015 .

[25]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Walewski,et al.  Relapsed or refractory primary mediastinal B-cell lymphoma: Evaluation of outcome of a minority from 125 patients treated at a single institution. , 2014 .

[27]  D. Speiser,et al.  Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells , 2014, Cancer Immunology Research.

[28]  Elaine S. Jaffe,et al.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.

[29]  P. Gaulard,et al.  Primary mediastinal (thymic) large B-cell lymphoma , 2008 .

[30]  R. Tsang,et al.  Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma , 2008, Leukemia & lymphoma.

[31]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[32]  R. Warnke,et al.  CD30 expression is common in mediastinal large B-cell lymphoma. , 1999, American journal of clinical pathology.

[33]  R. Houot,et al.  Outcomes after fi rst-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study , 2021 .

[34]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[35]  W. Wilson,et al.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? , 2015, Blood.

[36]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.